Clinical Trial Update: A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Poziotinib, a pan-HER inhibitor, for recurrent or metastatic esophageal squamous cell carcinoma; the trial status is unkn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Yonsei University | Conditions: Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma | Phase 2 | Status: UNKNOWN